Risk of Infections in Adult Patients with Haematological Malignancies

Mette Nørgaard*

Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Denmark

Abstract: Patients with haematological malignancies are at increased risk of infections not only because of the malignancy itself but also because of neutropenia induced by intensive chemotherapeutic treatment, and the cytotoxic effect on the cells that line the alimentary tract. In haematological malignancy patients with a compromised inflammatory response, the classic signs and symptoms of infection may be masked. The results of blood cultures therefore play an important diagnostic role. Bacteraemia is a relatively common serious complication occurring in around 15% of patients with haematological malignancies within the first years after diagnosis but the risk varies between different types of haematological malignancies. Other risk factors for bacteraemia are presence of mucositis, neutropenia, and use of central venous catheters. Invasive fungal diseases are also serious infectious complications in this population. Viral infections are particularly often in patients that have received a bone marrow transplant. Future work in this field could focus on potential modifiable risk factors and on how time since haematological diagnosis may influence risk of infection.

Keywords: Infection, bacteremia, neutropenia, haematological cancer, adults, epidemiologic factors.

INTRODUCTION

Infections remain a common complication in patients with haematological malignancies. These patients are at increased risk of infections not only because of the malignancy itself but also because of neutropenia induced by intensive chemotherapeutic treatment that may be followed by haematopoietic stem cell transplantation, and the cytotoxic effect on the cells that line the alimentary tract [1]. This review focuses on the risk of different types of infections in adults with haematological malignancies.

FEBRILE NEUTROPENIA

Febrile neutropenia is a medical emergency prompting immediate hospitalisation in most cases for assessment and treatment. The definition of febrile neutropenia varies but is generally regarded as presence of a fever>38°C with an absolute neutrophile count < 1.0 x 10^9/L [2]. Neutrophils make up over 90% of the circulating granulocytes in a normal individual and serve as the body’s primary defence against infections [3]. In a seminal study from 1965, Bodey et al. [4] followed 52 patients aged 1-77 years with a newly diagnosed acute leukaemia and found that the incidence of infectious episodes decreased with increasing levels of circulating granulocytes and lymphocytes. Fever and infections as a consequence of neutropenia mainly in acute leukaemia or agranulocytosis, were first described about 100 years ago [5]. In the 1960s, the attention to severe infections among patients with haematological or other malignancies increased, due to better antineoplastic treatment. Specific pathogens, such as Pseudomonas aeruginosa and Serratia marcescens, were recognised as specific challenges in oncologic treatment [6, 7]. At that time, mortality following P. aeruginosa bacteraemia was approximately 90%, in spite of the availability of antibiotics active in vitro [8]. According to PubMed, the term "empiric antibiotic therapy" was used for the first time in 1971 by Schimpff et al. in a paper on febrile patients with cancer and granulocytopenia [9]. The authors launched the concept that a combination of antibiotics active against P. aeruginosa and other Gram-negative bacilli should be given empirically as soon as neutropenic patients become febrile. In 1973 in Europe, the group of Klastersky at Jules Bordet Institute in Brussels initiated a series of randomised controlled multicenter trials under the auspices of The International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer (EORTC) [10-14]. These trials focused on finding the most superior antibiotic combination for empirical treatment. In the EORTC trials, the results were primarily evaluated based on patients with positive microbiological findings, which further focused the attention to patients with bacteraemia. In a EORTC-trial including 859 febrile neutropenic cancer patients, 218 (29%) of the patients had bacteraemia and 25 (3%) had microbiological documented infection without bacteraemia [15]. Because of the high mortality in patients with febrile neutropenia hospital treatment with close medical surveillance and ready availability of emergency care is considered crucial [16]. Neutropenic patients with fever are, however, a heterogeneous population with subsets of patients who have low risk of medical complications. Therefore attention has been paid to risk assessment models with the purpose of identifying patients with low risk who could be safely discharged to receive antibiotics at home [16]. Talcott et al. developed a prediction rule which classified inpatients, outpatients with serious comorbidity, and patients with uncontrolled cancer as high risk patients. Additional risk factors were age 40 years or greater and short latency from chemotherapy to fever and neutropenia [16]. Klastersky et
al. developed the multinational association for supportive care in cancer (MASCC) risk index based on a derivation cohort of 756 patients and validated in a cohort of 383 patients with febrile neutropenia [17]. Predictive factors were a burden of illness indicating absence of symptoms or mild symptoms (weight, 5); moderate symptoms (weight, 3); absence of hypotension (weight, 5); absence of chronic obstructive pulmonary disease (weight, 4); presence of solid tumour or absence of previous fungal infection in patients with haematologic malignancies (weight, 4); outpatient status (weight, 3); absence of dehydration (weight, 3); and age less than 60 years (weight, 2). Scores ≥21 identified patients with low risk [17]. This index has since then been validated in other populations [18, 19]. According to the Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer risk stratification is a recommended starting point for managing patients with fever and neutropenia [20].

**BACTERAEMIA**

Focal infections, such as pneumonia, acute cystitis, or perianal abscesses, occur in patients with haematological malignancies [21]. However, because of the compromised inflammatory response in these patients, the classic signs and symptoms of infection may be masked [22]. An elevated temperature may be its only clinical sign; thus, the results of blood cultures play a pivotal diagnostic role.

Whereas Gram-negative bacteria (*Escherichia coli, Klebsiella spp, and P. aeruginosa*) were predominant in neutropenic cancer patients in the 1970s and early 1980s [23], Gram-positive bacteria (coagulase-negative staphylococci and viridans streptococci) became progressively prevalent in the late 1980s and early 1990s [24]. Some of the factors implicated in the increasing number of Gram-positive bacteraemias were the administration of aggressive chemotherapy and radiotherapy regimens that induced severe mucositis, increased use of indwelling catheters, the widespread use of fluoroquinolones as prophylactic agents, and empirical antibiotic treatment with high activity against Gram-negative infections [25-27]. Yet, this shift towards Gram-positive bacteraemias has not been global. Chen et al. demonstrated in 7058 patients admitted to the haemato-oncological department at National Taiwan Hospital between 2002 and 2006 that 60% of the bacteraemias in neutropenic patients were caused by Gram-negative infections [28] and a similar pattern was demonstrated by Gupta et al. in a study from India [29].

The change in spectrum of microorganisms causing bacteraemia has likewise been more unequivocal in studies including non-neutropenic haematological patients as well [24]. These differences show that reliance solely on data on bacteraemias from other countries/institutions may be misleading and emphasise the need for frequent monitoring and surveillance at institutions treating large numbers of patients with neutropenia [30, 31].

Moreover, increasing rates of drug resistance among both gram-positive and gram-negative pathogens are being documented globally [26, 32, 33]. This includes methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococcus (VRE), extended-spectrum beta-lactamase (ESBL) -producing gram-negative bacteria, and carbapenemase-producing organisms, including Klebsiella pneumoniae carbapenemase (KPC) [20].

The administration of parenteral, broad-spectrum empirical antibiotic therapy after hospitalisation of patients with febrile neutropenia is the accepted standard of care [20]. Risk assessment may determine the type of empirical antibiotic therapy (oral vs intravenous), the venue of treatment (inpatient versus outpatient), and duration of antibiotic therapy. Drug resistance must, however, also be taken into consideration when prophylaxis and empirical therapy are being considered. One strategy consists of maximising initial empirical coverage with subsequent reduction or streamlining (de-escalation) of the regimen based on clinical and microbiological data [30]. Another strategy could be to restrict use of e.g. use of third generation cephalosporins or carbapenems which are associated with high risk of promoting multidrug resistance. However, it may not be practical to restrict several classes of drugs in order to reduce the emergence of resistance [30]. Instead equal use of multiple classes of antimicrobial agents has been suggested and successfully used e.g. in the M. D. Anderson Cancer Center [30].

Since purulence, fluctuation, or lung infiltrates may not develop in patients with haematological malignancies the focus of bacteraemia often remains unknown [34]. Failure to determine the source of infection is associated with increased mortality in patients with bacteraemia [34]. At the same time, Pittet et al. found that pneumonia as a source of infection was associated with increased mortality in nosocomial bloodstream infections [35]. Likewise, Gonzales-Barca et al. found that pneumonia – defined as the presence of acute respiratory illness and pulmonary infiltrate – as the focus of bacteraemia was associated with a higher risk of mortality among neutropenic patients (OR, 4.4 (95% CI: 1.9-10)) [36]. In the latter study, however, the authors did not address the impact of an unknown focus. For patients with haematological malignancies bacteraemia is widely regarded as a major risk factor for mortality [1]. A population-based study from Denmark included 7456 patients, who were admitted to hospital with their first episode of bacteraemia. Of these, 444 patients had a haematological malignancy. Compared with patients without a malignancy diagnosis patients with a haematological malignancy had a higher mortality (adjusted mortality rate ratio = 1.6 (95% CI, 1.3-2.0)). Their mortality did not differ substantially from the mortality in patients with other types of malignancies [37].

**HAEMATOLOGICAL MALIGNANCIES AND INCIDENCE OF BACTERAEMIA**

Little formal epidemiological evidence exists on the magnitude of the incidence of bacteraemia among patients with haematological malignancies. One study, reported in Spanish by Teira et al., computed incidence rates of bacteraemia among haematological patients admitted at one haemalogical department [38]. Of the 244 newly diagnosed cases of acute myeloid leukaemia or lymphoma 53 admitted patients were lost to follow-up. In the remaining 191 patient the incidence rate of bacteraemia, expressed as cases per 1000 patient-days, was 5.8 for AML and 0.21 for high-grade
malignant lymphoma [39]. In a Danish study Nørgaard et al. found that among 1,666 patients with a first haematological malignancy, 358 (21%) had a successive episode of bacteraemia during a mean follow-up of 2.2 years, yielding an overall incidence rate of 96 per 1000 years [34]. In 246 (15%) of the patients the first episode of bacteraemia occurred within a year after haematological malignancy diagnosis. The cumulative incidence of bacteraemia did, however, differ between the different types of haematological malignancies within the first year of follow-up. When compared with Hodgkin’s disease patients, the incidence rate ratios [IRRs] for bacteraemia were 23.3 (95% CI: 10.0-54.5) for acute myeloid leukaemia, 3.8 (95% CI: 1.5-9.3) for multiple myeloma, 2.2 (95% CI: 0.9-5.1) for non-Hodgkin lymphoma or chronic lymphatic leukaemia, and 8.3 (95% CI: 3.5-19.6) for others, all adjusted for age, gender, and comorbidity [34]. Similarly, in an American study including 365,014 patients hospitalised with haematological malignancies, of whom 64,684 developed severe sepsis the relative risks (RRs) of severe sepsis showed large variation between the different types of haematological malignancies, with Hodgkin’s disease having the smallest (RR=1.0) and acute myeloid leukaemia the largest risk of severe sepsis (RR= 65.2) [35].

RISK FACTORS FOR BACTERAEMIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCES

Other factors than type of haematological malignancy may influence the risk of bacteraemia in patients with haematological malignancies. In a case-control study by Pagano et al., use of central venous catheter (OR 6.1,95% CI: 1.3-12.3) and neutropenia for more than six days (OR 3.0, 95% CI: 1.7-9.5) were found to be risk factors for bacteraemia in patients with haematological malignancies [40]. In a study of 104 patients with haematological malignancies and 253 patients with solid tumours Pedersen et al. found that after placement of their first central venous catheter device patients with haematological malignancies had 10-fold increased risk of bacteraemia compared with patients with solid tumours (RR=10.8 95%; CI, 5.8-20.1) [41]. Ruescher et al. conducted a case-control study among recipients of autologous bone marrow transplantation and found patients with ulcerative mucositis to be three times as likely to develop alpha-hemolytic streptococcal bacteremia as those without ulcerative mucositis (OR =3.02) [36]. In a randomised controlled trial among neutropenic cancer patients Bucaneve et al. found prophylactic use of fluorquinolones to be associated with an absolute decrease in risk of bacteraemia, risk difference -0.16 (95% CI: -0.22 to -0.09) [42].

Apostolopolou et al. computed incidence rates of bacteraemia among 102 patients with haematological malignancies who were hospitalised for more than 48 hours [43]. They found an overall bacteraemia incidence of 21.99 per 1000 patient days at risk. The patients who developed bacteraemias were mainly women. In contrast, age did not seem to predict bacteraemia [43]. Garcia-Suarez et al. also found similar rates of infection in elderly and in younger haematological cancer patients with febrile neutropenia in a study of 131 consecutive episodes of fever and chemotherapy-induced neutropenia in 85 adults with haematological malignancies [43]. Age is, however, shown to be a risk factor for development of severe neutropenia [1]. Few, if any, data exist on the impact of comorbidity as a risk factor for bacteraemia in patients with haematological malignancies.

CANDIDAEMIA

Although the incidence of invasive candida infections has decreased with the prophylactic use of azole drugs that was introduced in the 1990’s candidemia remains a serious disease in patients with haematological malignancies. At the M.D. Anderson Cancer Center the incidence of candidemia per 100,000 in-patients days varied between 13.9 and 23.2 in the period 2001 to 2006 [44]. Marr and colleagues found a cumulative incidence of candidemia of 4.6% following bone marrow transplantation [37]. Over time, candidemia strains have shifted from Candida albicans toward non-albicans species such as C. krusei, C. glabrata, C. parapsilosis, and C. tropicalis [44]. The candidemias are most often acquired endogenously through invasion of the gastrointestinal tract [45] or as a catheter-related infection [44]. According to the IDSA guidelines, empirical antifungal coverage should be considered in high-risk patients who have persistent fever after 4–7 days of a broad-spectrum antibacterial regimen and no identified fever source [20].

RESPIRATORY TRACT INFECTIONS

In a Turkish study including 1,132 patients with haematological malignancies who were referred to an infectious disease team for suspected infection, pneumonia was detected in 173 cases and was the most common clinically documented infection [46]. Still, no formal epidemiological data exist on the incidence of pneumonia in patients with haematological malignancies. Pulmonary complications are particular common following haematopoietic stem cell transplantation. Puig et al. identified 49 episodes of pneumonia in 326 adult Spanish patients who underwent autologous stem cell transplantation from 1990 to 2005[47]. Multiple myeloma and neutropenia lasting for more than 7 days predicted a higher risk for pneumonia. No pathogen could, however, be isolated in 38 (76%) of these cases [47].

Respiratory syncytial virus, Influenza A and B viruses, and parainfluenza viruses are all widely described as causes of severe respiratory infections in patients with haematological malignancies [48]. But also human enterovirus and human rhinovirus respiratory tract infections are in a Spanish study described as being relatively common in haematological patients [49].

In the recent years focus has been on severity of influenza in patients with haematological malignancies. In a study including 100 immunocompromised patients hospitalised with upper respiratory tract infection due to Influenza a haematological malignancy diagnosis predicted a high risk of progression to pneumonia [50]. Although, the utility of influenza vaccination in patients with haematological malignancy remains controversial [48] recent conclusions have been that patients with cancer receiving chemotherapy are able to respond to influenza vaccination, and because this intervention is safe, inexpensive, and widely available, vaccination for seasonal influenza and the novel H1N1 strain is indicated [51]. According to the IDSA guidelines yearly influenza vaccination with inactivated
vaccine is recommended for all patients being treated for cancer [20].

Pulmonary aspergillosis is the major cause of fungal induced mortality in patients with haematological malignancies but organisms such as Candida species, Trichosporon species, Cryptococcus species, and Pneumocystis jirovecii may also cause fungal pneumonia [52].

OTHER VIRAL INFECTIONS

Herpes simplex viruses (HSV) are common complications among patients with haematological malignancies who are undergoing stem-cell transplantation or receiving myelosuppressive chemotherapy. Up to 80% of adult patients with leukaemia are HSV seropositive and the incidence of HSV lesions among seropositive patients receiving chemotherapy for acute leukaemia has been found to be above 60% [53]. The risk of HSV disease after allogeneic stem cell transplantation without prophylaxis is approximately 80% [54]. This relates almost exclusively to virus reactivations during the first few weeks after stem cell transplantation during bone marrow aplasia or in the presence of stomatitis [53].

In varicella-zoster virus (VZV)–seropositive recipients of bone marrow transplantation the risk of developing herpes zoster between 3-12 months after the transplantation is 10-68% [53]. Prophylactic antiviral treatment has been shown to reduce the incidence of VZV infections in the pre- and post-engraftment period, but in only one trial that examined the effect of antiviral treatment during episodes of intensive chemotherapy no effect was reported [55].

In the absence of effective antiviral prophylaxis, the incidence of Cytomegalovirus (CMV) infection among patients with haematological malignancy ranges from 5–75% [56]. T-cell function is paramount in the control of CMV, and T-cell depleting agents (e.g., alemtuzumab) and aggressive chemotherapy appear to increase the risk of CMV infection and disease [48]. The incidence of CMV infection and disease is less clearly defined for patients with haematological malignancies who receive conventional therapy. Investigators at the MD Anderson Cancer Center have reported an overall increase in CMV gastrointestinal disease [57], and CMV pneumonia among patients with lymphoma [58] and acute leukemia [59]. In the absence of effective antiviral prophylaxis, the incidence of CMV infection among patients with haematological malignancy ranges from 5–75%. Late CMV infection after haematopoietic stem cell transplant is seen in 3–17% of allogeneic transplant recipients [60].

GASTROINTESTINAL INFECTIONS

Neutropenic enterocolitis (in the early 1970’s referred to as typhilitis) is the most important clinical entity among abdominal infections in neutropenic adults [61]. This acute inflammatory disease may involve coecum, colon, and the terminal part of ileum. Neutropenic enterocolitis is reported to occur in 0.8% to 26% of neutropenic episodes and the case fatality has been reported to be 50% or higher [61]. The clinical presentation of neutropenic enterocolitis is broad with patients with proven imaging findings having more severe disease [62]. The need for radiological confirmation is discussed but recommended by many authors [61]. Patients with mural thickening detected sonographically or by computerized tomography scan have a poorer prognosis than patients without this finding [63].

TIME SINCE HAEMATOLOGICAL MALIGNANCY DIAGNOSIS AND RISK OF INFECTION

Little is known about the risk of infections among long-term survivors of haematological malignancies. Gradel et al. found that, compared with the background population, patients with haematological malignancies had a 7-8 fold risk of hospitalisation with Salmonella or Campylobacter gastroenteritis in the 2 years after their malignancy diagnosis and a 4-5 fold increased risk in the period 3-5 years after malignancy diagnosis [64]. This study thus suggested an increased long-term risk of infection but the study did not distinguish between patients who were in remission and patients with active disease. Teodorescu et al. followed 209 patients who were diagnosed with hairy cell leukaemia in the period from January 1997 to August 2007 in Denmark for a median of 4.5 years [65]. Compared with an age and sex-matched general population cohort patients with hairy cell leukaemia had an increased risk of hospitalisation with pneumonia or bacteremia [65]. The adjusted RR of infection was 8.04 (95% CI: 4.99-12.95) the first year after diagnosis and 1.17 (95% CI: 0.71-1.94) for the remaining follow-up period. This suggested that more than one year after diagnosis patients with hairy cell leukaemia have a similar risk of infections as the general population.

CONCLUSION

Despite improved survival during the last decades patients with haematological malignancies are still at high risk of infectious complications. Bacteraemia and candidaemia are serious complications and the use of prophylaxis may lead to a higher prevalence of more resistant strains. Viral complications are most common following bone marrow transplantation. Little is known about the risk of infection in long-term survivors.

ACKNOWLEDGEMENT

Declared none.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

REFERENCES


